Vertex Casgevy Approved for Kids 2+, First Pediatric CRISPR

The FDA expanded Vertex Pharmaceuticals’ (VRTX) Casgevy (exagamglogene autotemcel) on July 1, 2026, to treat patients ages 2 years and older with sickle cell disease (SCD) who have recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT). Casgevy is the first and only approved genetic therapy for children as young as 2 for both conditions.

The FDA approved the expansion 53 days after filing, under the Commissioner’s National Priority Voucher (CNPV) program. That is among the fastest review timelines for a gene therapy supplement. The CNPV program was established by former FDA Commissioner Marty Makary before his resignation in May. Casgevy is one of the first therapies approved through this expedited pathway.

What changed from the original approval

Casgevy was originally approved in December 2023 for patients ages 12 and older. The expansion down to age 2 makes approximately 5,500 additional children in the U.S. eligible for this one-time CRISPR/Cas9 gene therapy.

The clinical basis comes from the CLIMB studies. In the 5-to-11-year-old cohort with SCD, all eight evaluable patients achieved no severe vaso-occlusive crises for at least 12 consecutive months. In a separate TDT trial, eight of nine evaluable patients achieved transfusion independence for 12 months.

Treating earlier matters clinically. SCD causes progressive organ damage from repeated vaso-occlusive crises. Intervening before that damage accumulates gives children a better chance at a healthier life.

The risks are not trivial. Casgevy requires busulfan conditioning chemotherapy, which carries infertility and infection risks. Patients spend weeks hospitalized for the stem cell collection and modified-cell infusion. At $2.2 million per treatment, insurance coverage is not guaranteed. These barriers explain why uptake has been slow even in the original 12-and-older population.

For more on FDA expedited review programs, see our guide to PDUFA dates.

The CNPV program

The Commissioner’s National Priority Voucher is a new FDA expedited review mechanism that most investors have not encountered. Casgevy’s 53-day review under CNPV stands against standard reviews of 10 months and priority reviews of six. The program’s future is uncertain. Makary resigned in May 2026, and it is unclear whether the next FDA commissioner will maintain the initiative.

What this means for Vertex

Expanding the eligible population by 5,500 children increases the revenue ceiling, though the bottleneck is manufacturing capacity and the network of authorized treatment centers. Vertex says 75 ATCs are now activated in the U.S. The gene therapy franchise is part of a broader diversification beyond cystic fibrosis, including the recently announced $10 billion acquisition of Crinetics Pharmaceuticals. Vertex closed at $473.09 on July 24, with a market cap of approximately $120 billion.

What to watch next

1. Treatment uptake: How quickly the 5,500 newly eligible patients begin treatment depends on parent awareness, ATC capacity, and insurance coverage.
2. CNPV continuity: Whether the next FDA commissioner maintains the program affects future accelerated reviews.
3. Competitive dynamics: bluebird bio’s Lyfgenia was approved alongside Casgevy in 2023 for SCD but has not pursued a pediatric expansion. Vertex leads in younger patients for now.

Source: Vertex press release | FDA announcement

What It Means for the Trade

The label expansion’s arithmetic is straightforward: 5,500 newly eligible children raises Casgevy’s theoretical revenue ceiling meaningfully, but theoretical is the operative word — the original 12-and-older label produced slow uptake, and the pediatric market will move at the pace of parent conviction, ATC activation, and payer coverage, not at the pace of FDA review. Fifty-three days under CNPV tells you regulatory enthusiasm is maximal; commercial enthusiasm remains the constraint. Vertex at $473 prices Casgevy as a slow-building franchise inside a CF-plus-diversification story, which is the right frame.

The strategically interesting read is the CNPV program itself. A 53-day gene-therapy supplement is precedent-setting speed, and every Vertex (and competitor) gene-therapy filing that qualifies for priority mechanisms now has a demonstrated fast lane. If the next commissioner keeps the program, expedited review becomes a competitive weapon in cell and gene therapy; if it dies with Makary’s departure, this approval is a historical footnote. Either way Vertex banked the benefit first.

For the diversification thesis: Casgevy, Journavx, the Crinetics acquisition — Vertex is deliberately building a multi-franchise rare-disease and specialty company beyond CF. Pediatric Casgevy is a small piece but a clean one: the same manufacturing and ATC network serves both populations.

Mechanism and Market Context

Casgevy edits the BCL11A erythroid enhancer in patient-derived hematopoietic stem cells, reactivating fetal hemoglobin — the switch that turns on the body’s own workaround for defective adult hemoglobin. One-time editing removes the need for lifelong transfusion support in TDT and eliminates vaso-occlusive crises in SCD. The pediatric rationale is strong medicine: SCD organ damage — spleen, kidneys, brain vasculature — accumulates crisis by crisis, so treating at 2-6 years prevents damage that treating at 12 can only stabilize. The CLIMB cohort data (8/8 SCD patients crisis-free, 8/9 TDT patients transfusion-independent for 12 months) is small-sample but directionally decisive in a disease where natural history is well documented.

The bottleneck is the delivery infrastructure: busulfan conditioning (infertility and infection risk), weeks of hospitalization, authorized-treatment-center capacity (75 activated), and a $2.2 million price that demands case-by-case payer negotiation per child. Pediatric dosing is not simpler — families weighing a myeloablative procedure on a young child move slowly, and correctly so.

Risks and What Could Go Wrong

1. Uptake remains slow. If the 12-plus population’s tepid conversion is any guide, the pediatric expansion adds eligible patients faster than treated patients; revenue ceiling rises, floor does not.
2. CNPV program uncertainty. The 53-day precedent dies if the program dies; future expansions revert to standard clocks.
3. Payer pushback on pediatric pricing. A $2.2 million one-time therapy in a child triggers both coverage debate and Medicaid budgeting friction — the population most SCD patients rely on.
4. Competing curative approaches. Gene-addition and other editing programs target younger cohorts too; first-mover advantage in pediatrics has a shelf life.

Net: a fast, clinically sound expansion that raises the ceiling more than the floor. The Vertex trade remains launch-curve execution and the broader pipeline, with Casgevy as patient compounding optionality.